Collegium Pharmaceutical, Inc.

Pierce Management LLC

Peirce Management, LLC

Peierce Management LLC

Mark Hirsh

Kamal K Midha

Whe-Yong Lo

Jane C Hirsh

Hans E Junginger

Hans E Junginer

Compositions containing both a sedative compound and a non-sedative antihistamine are provided. More particularly, compositions for administration at bedtime containing a sedating antihistamine or other sedating compound in immediate release form and a non-sedating antihistamine in delayed-release form are described. Alternatively, a composition, for administrating upon awakening, containing a non-sedating antihistamine in immediate release form, and a sedating antihistamine or other sedative in delayed-release form is described. Methods of inhibiting the release of histamines by administration of the compositions to a mammalian subject are also provided. The dosage forms may comprise other medications, such as leukotriene receptor antagonists, to enhance the suppression of histamine symptoms.

Compositions containing both sedative and non-sedative antihistamines and sleep aids

New pharmaceutical compositions in unit dosage form are disclosed for both intraoral and oral administration to a patient, said unit dosage form configured to be placed intraorally of said patient, which comprises:

Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration

Compositions comprising both a sedative and a non-sedative antihistamine are disclosed as well as methods of inhibiting the release of histamines by administration of the compositions to a mammalian subject.

Compositions containing both sedative and non-sedative antihistamines

Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart &ldquo;pulses.&rdquo; The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a &ldquo;coated core&rdquo; dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.

Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Pharmaceutical composition containing two active ingredients for smoking cessation

The invention includes a patch and method for transdermal delivery of bupropion base. In the method of this invention, a patient is administered a bupropion base in an amount effective to alleviate withdrawal symptoms and to prevent or reduce craving of nicotine in said patient. Alternatively, an effective amount of bupropion base is delivered to alleviate depression in a patient or to treat obesity. A transdermal patch includes a bupropion base. The bupropion base can be mixed with an acceptable pharmaceutical carrier.

Patch and method for transdermal delivery of bupropion base

The invention includes an apparatus and method for transdermal delivery of bupropion base. In the method of this invention, patient is administered parenterally a bupropion base in an amount effective to alleviate withdrawal symptoms and to prevent or reduce craving of nicotine in said patient. Alternatively, an effective amount of bupropion base is delivered to alleviate depression in a patient. A transdermal delivery system includes a bupropion base. The bupropion base can be mixed with an acceptable pharmaceutical carrier.

Growing community of inventors

Wellesley, MA, United States of America

Mark Hirsh